文献速递乳腺癌

低激素受体阳性早期乳腺癌的治疗反应与预后:2765例新辅助临床试验分析

Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
PubMed 文献 · Eur J Cancer · 2021-03-18

该研究基于2765例新辅助临床试验队列,比较激素受体(HR)阴性、低阳性(1-9%)和强阳性(10-100%)HER2阴性乳腺癌的病理完全缓解(pCR)与生存。低HR阳性肿瘤占比3.4%,其pCR率(27.7%)与三阴性乳腺癌(35.5%)无显著差异,DFS和DDFS亦无差异;强HR阳性肿瘤pCR率更低但生存更优。RNA测序显示低HR阳性肿瘤主要归为基底样亚型(86.8%)。结论认为低HR阳性肿瘤临床行为类似三阴性乳腺癌,应考虑针对三阴性乳腺癌的治疗策略。

要点

  • 低HR阳性(1-9%)HER2阴性乳腺癌的pCR率、DFS和DDFS与三阴性乳腺癌无显著差异。
  • 低HR阳性肿瘤RNA测序主要归为基底样亚型(86.8%)。
  • 低HR阳性患者应考虑采用针对三阴性乳腺癌的治疗策略。

核心结论

  • 低HR阳性HER2阴性乳腺癌临床行为类似三阴性乳腺癌,表现为高pCR率和较差生存,且基因表达呈基底样特征。

研究设计与样本

  • 研究比较了新辅助临床试验队列(n=2765)中HR阴性(ER和PR<1%)、低阳性(ER和/或PR 1-9%)和强阳性(ER或PR 10-100%)乳腺癌患者的pCR与生存。
  • 对38例低HR表达患者的肿瘤组织进行了RNA测序。

主要发现

  • 低HR阳性与三阴性乳腺癌的pCR率分别为27.7%和35.5%,无显著差异。
  • 低HR阳性与三阴性乳腺癌的DFS无差异(HR 1.26,95%CI 0.87-1.83,log-rank p=0.951),DDFS无差异(HR 1.17,95%CI 0.78-1.76,log-rank p=0.774)。
  • 强HR阳性肿瘤pCR率显著更低(9.4%;OR 0.38,95%CI 0.23-0.63),但DFS(HR 0.48,95%CI 0.33-0.70)和DDFS(HR 0.49,95%CI 0.33-0.74)优于低HR阳性。
  • 低HR阳性肿瘤RNA测序主要归类为基底样亚型(86.8%)。

临床怎么用

  • 低HR阳性(1-9%)HER2阴性早期乳腺癌应视为三阴性乳腺癌候选人群,采用针对三阴性乳腺癌的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To evaluate HER2-negative breast cancer (BC) with a low hormone receptor (HR) expression, with regard to pathological complete response (pCR) and survival, in comparison to triple-negative BC (TNBC) and strong HR-positive BC. METHODS: We compared negative [oestrogen (ER) and progesterone receptor (PR) <1%], low-positive (ER and/or PR 1-9%) and strong-positive (ER or PR 10-100%) HR-expression in neoadjuvant clinical trial cohorts (n = 2765) of BC patients. End-points were disease-free survival (DFS), distant-disease free survival (DDFS) and overall survival (OS). We performed RNA sequencing on available tumour tissue samples from patients with low-HR expression (n = 38). RESULTS: Ninety-four (3.4%) patients had low HR-positive tumours, 1769 (64.0%) had strong HR-positive tumours, and 902 (32.6%) had TNBC. There were no significant differences in pCR rates between women with low HR-positive tumours (27.7%) and women with TNBC (35.5%). DFS and DDFS were also not different [for DFS, hazard ratio 1.26, 95%-CI (confidence interval) : 0.87-1.83, log-rank test p = 0.951; for DDFS, hazard ratio 1.17, 95%-CI: 0.78-1.76, log-rank test p = 0.774]. Patients with strong HR-positive tumours had a significantly lower pCR rate (pCR 9.4%; odds ratio 0.38, 95%-CI: 0.23-0.63), but better DFS (hazard ratio 0.48, 95%-CI: 0.33-0.70) and DDFS (hazard ratio 0.49, 95%-CI: 0.33-0.74) than patients with low HR-positive tumours. Molecular subtyping (RNA sequencing) of low HR-positive tumours classified these predominantly into a basal subtype (86.8%). CONCLUSION: Low HR-positive, HER2-negative tumours have a similar clinical behaviour to TNBC showing high pCR rates and poor survival and also a basal-like gene expression signature. Patients with low HR-positive tumours should be regarded as candidates for therapy strategies targeting TNBC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Villegas SL, Nekljudova V, Pfarr N, et al. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials. Eur J Cancer. 2021. PMID: 33743484. doi:10.1016/j.ejca.2021.02.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。